Xeljanz access in Pakistan: the DRAP named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Pakistan access Xeljanz (tofacitinib) for the treatment of adults with moderately-to-severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderately-to-severely active ulcerative colitis, and the treatment of polyarticular course juvenile idiopathic arthritis in patients 2 years of age and older through the DRAP named-patient pathway, a Drug Regulatory Authority of Pakistan-administered mechanism that allows a Pakistani-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in PKR.

Reserved for you.

Why Pakistani patients need Xeljanz through the named-patient pathway

the Islamic Republic of Pakistan operates a structured pharmaceutical regulatory environment. Xeljanz (tofacitinib) is regulated through DRAP (Drug Regulatory Authority of Pakistan) channels, and a Pakistani family asking for Xeljanz is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.

Four converging patterns drive these cases. First, indication lag. Xeljanz's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. EFU Health and Jubilee General and Adamjee Insurance each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Pakistan or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.

In each pattern, the DRAP named-patient pathway is the mechanism that connects a Pakistani-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Xeljanz is an oral, small-molecule Janus kinase inhibitor that preferentially inhibits JAK1 and JAK3 (with lesser activity against JAK2 and TYK2), blocking signal transduction downstream of cytokine and growth-factor receptors implicated in immune-mediated inflammation, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.

The DRAP named-patient pathway for Xeljanz

The pathway for a Pakistani-licensed physician to obtain a medicine that is not registered or not stocked locally is the DRAP Special Permission / Non-Objection Certificate pathway, which allows a treating physician at a registered tertiary facility to apply for the import of an unregistered medicine for a specific named patient, filed through the DRAP OIES portal at dra.gov.pk and administered under the DRAP Act 2012. The framework allows registered healthcare facilities to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable. For Xeljanz specifically, the clinical justification typically frames the case around the precise FDA-approved indication and the documented gap in the local route.

A complete application includes a clinical justification letter from the treating physician (diagnosis, severity, prior therapies, why this specific drug, why the locally stocked option is not suitable for this case), the treating physician's Pakistani medical license verification through the Pakistan Medical and Dental Council (PMDC) and DRAP, an anonymised patient identifier where the DRAP submission allows, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity requested, intended treatment duration), the destination dispensing facility name, license number, and pharmacy in charge, and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy.

For Xeljanz, the clinical justification angle typically rests on one or more of three documented elements: a pediatric or weight-banded request that fits the FDA label but not the local label, a denied biologic or specialty claim where prior step-therapy has been documented, or a continuity-of-supply request for a patient previously stabilised on the US-sourced presentation. The treating physician documents the relevant clinical criteria for the prescribed indication: severity scores, biomarker levels, prior therapy failures, and the rationale for Xeljanz versus the next-in-line local alternative.

Approval timelines for routine cases are typically 14 to 35 business days. Complex cases (rare indication, larger quantities, first import of a given pediatric or weight-banded format) can extend to 8 to 12 weeks. DRAP retains discretion on timing, and we do not promise specific durations.

Where Xeljanz gets dispensed in Pakistan

A small group of Pakistani institutions handle named-patient imports as established workflow, with in-house import pharmacy infrastructure and physicians experienced with the application set. Tertiary and major private hospitals that meet this profile include Aga Khan University Hospital (AKU) Karachi Rheumatology Section, Shaikh Zayed Hospital Lahore Rheumatology Department, and Shifa International Hospital Islamabad Rheumatology. Each maintains pharmacy infrastructure appropriate to the storage requirements of the imported medicine (2 to 8 degrees Celsius cold-chain for biologics, ambient storage for oral therapies, ultra-cold or specialised handling where the FDA label requires it).

For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a specialty importer that holds a pharmaceutical establishment license and files the DRAP application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's outpatient or specialty pharmacy under chain-of-custody documentation.

Real cost picture for Xeljanz in Pakistan

US WAC for Xeljanz runs in the range of USD 59,800 to USD 70,200 per year at the standard FDA-labelled regimen for the treatment of adults with moderately-to-severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderately-to-severely active ulcerative colitis, and the treatment of polyarticular course juvenile idiopathic arthritis in patients 2 years of age and older. PKR is trading at approximately 278 PKR to 1 USD, so the annual reference range converts to roughly PKR 16,624,000 to PKR 19,516,000 for the drug itself at US WAC equivalents.

International logistics for shipment to Pakistan typically runs USD 350 to USD 1100 depending on destination city, urgency, and presentation (cold-chain biologics carry the higher end of the range; ambient oral solids the lower). the Islamic Republic of Pakistan customs and DRAP permit fees are nominal relative to drug cost. Reserve Meds' concierge fee is itemised separately on every firm quote.

On the insurance side, EFU Health and Jubilee General and Adamjee Insurance each assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We do not promise coverage from any insurer. US manufacturer copay cards and patient assistance programs do not extend internationally; cross-border patients pay cash or rely on local payer coverage.

Typical timeline for Xeljanz in Pakistan

DRAP routine processing is typically 14 to 35 business days from a complete filing. International logistics adds 2 to 5 additional days depending on whether the presentation is ambient or cold-chain, the dispensing city, and customs clearance. End-to-end, most routine adult cases complete within 3 to 6 weeks from first complete documentation. Pediatric, weight-banded, or first-import cases can run slightly longer because presentation selection and first-import scrutiny can extend DRAP review.

For temperature-sensitive products, the dispensing facility must maintain validated storage with continuous monitoring; the manufacturer's room-temperature excursion runway on the FDA label informs how we plan the Gulf, South Asia, or North Africa shipping lane, and the cold chain is broken only at the dispensing pharmacy under documented control.

When a case is on a clinical clock (a flare, a new diagnosis with an active disease, or a treatment cycle scheduled at the dispensing centre), the practical question is which step controls the timeline. In our experience the binding step is rarely the DRAP review itself when the application is filed clean; it is usually documentation completeness on the prescriber's side or, for cold-chain biologics, the dispensing facility's storage and monitoring confirmation. The waitlist intake is where we lock the case-team contact, gather the documents in parallel, and start the US sourcing clock so that approval and product land in the same week rather than serially.

What your physician needs to provide

For a Pakistani-licensed specialist prescribing Xeljanz through the DRAP pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for the treatment of adults with moderately-to-severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderately-to-severely active ulcerative colitis, and the treatment of polyarticular course juvenile idiopathic arthritis in patients 2 years of age and older, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Xeljanz is the appropriate next step given an oral, small-molecule Janus kinase inhibitor that preferentially inhibits JAK1 and JAK3 (with lesser activity against JAK2 and TYK2), blocking signal transduction downstream of cytokine and growth-factor receptors implicated in immune-mediated inflammation.

The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Xeljanz (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.

The treating physician's Pakistani license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.

Common questions about Xeljanz in Pakistan

Will EFU Health and Jubilee General and Adamjee Insurance cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Xeljanz is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DRAP? The DRAP named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DRAP review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Pakistani-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. the Pakistan Medical and Dental Council (PMDC) and DRAP verifies the active license; the DRAP application records both the prescribing physician and the dispensing facility.

Can I receive Xeljanz at home? The dispensing facility must be Pakistani-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Where Reserve Meds fits in Xeljanz cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DRAP, and we do not replace your dispensing pharmacy. For Xeljanz specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Pakistan, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Xeljanz case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DRAP application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Xeljanz is administered orally as 5 mg twice daily or 11 mg once daily (extended-release) for most indications, with an induction-then-maintenance regimen for ulcerative colitis per the labelled schedule; rheumatology or gastroenterology follow-up tracks DAS28, ACR, or partial Mayo response, infection screening (tuberculosis baseline), CBC, lipid panel, and the labelled boxed warning for serious infections, malignancy, MACE, thrombosis, and mortality observed in the ORAL Surveillance study.

Next step

If your Pakistani physician has prescribed Xeljanz and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Reserved for you.

---

Related

• Xeljanz drug overview
• Pakistan country page
• Named-patient pathway overview